Key Resources

Explore our library of presentations, brochures and relevant publications in our library


In this white paper you will discover how human induced pluripotent stem cell derived hepatocyte-like cells (HLCs) have the potential to act as an ideal model for the study of liver diseases, combining the expansion capacity and phenotypic stability of hepatoma cell lines with the functionality and normal karyotype of primary hepatocytes.


Within the white paper you will also learn more about DefiniGEN’s iPSC-derived HLC platform which is capable of screening candidate therapeutics with high accuracy and reproducibility.


DefiniGEN White Paper

Founder Publications

OptiDIFF technology is firmly rooted in the rigorous scientific studies of DefiniGEN founder Ludovic Vallier, PhD. Prof. Vallier and his lab pioneered the ability to differentiate human stem cells into hepatocytes, and the scientists at DefiniGEN have turned this work into a streamlined and scalable commercial process.

Generation of Hepatocytes from Pluripotent Stem Cells for Drug Screening and Developmental Modeling.
Maturation of Induced Pluripotent Stem Cell Derived Hepatocytes by 3D-Culture
Generation of Multipotent Foregut Stem Cells from Human Pluripotent Stem Cells
Human Pluripotent Stem Cells for Modelling Human Liver Diseases and Cell Therapy
Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells
Advance your scientific discoveries with our disease model development and screening services.